Información del artículo
Resumen
El uso de antibióticos en el ámbito hospitalario implica la adecuada dosificación teniendo en cuenta el comportamiento farmacocinético y farmacodinámico. El debate acerca del adecuado uso de polimixinas se ha abierto nuevamente dada la aparición de microoganismos multirresistentes.
Palabras clave:
Polimixina
Colistina
Antibióticos polipeptídicos
Sulfato de colistina
Base activa de colistina
Microorganismos multirresistentes
Abstract
The use of antibiotics in hospitals involves an adequate dosage that takes into account the pharmacokinetic and pharmacodynamic profile of these molecules. The debate on the correct use of polymyxins has been renewed, due to the emergence of multiresistant microorganisms.
Keywords:
Polymyxin
Colistin
Polypeptide antibiotics
Colistin sulphate
Active base colistin
Multidrug-resistant microorganisms
Artículo
Opciones para acceder a los textos completos de la publicación Acta Colombiana de Cuidado Intensivo
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
A.C. Gales, M. Castanheira, R.N. Jones, H.S. Sader.
Antimicrobial resistance among gram-negative bacilli isolated from Latin America: Results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010).
Diagn Microbiol Infect Dis., 73 (2012), pp. 354-360
[2]
G.M. Rossolini, F. Arena, P. Pecile, S. Pollini.
Update on the antibiotic resistance crisis.
Curr Opin Pharmacol., 18 (2014), pp. 56-60
[3]
P.G. Stansly, R.G. Shepherd, H.J. White.
Polymyxin: A new chemotherapeutic agent.
Bull Johns Hopkins Hosp., 81 (1947), pp. 43-54
[4]
A. Kwa, S.K. Kasiakou, V.H. Tam, M.E. Falagas.
Polymyxin B: Similarities to and differences from colistin (polymyxin E).
Expert Rev Anti Infect Ther., 5 (2007), pp. 811-821
[5]
J.A. Orwa, C. Govaerts, R. Busson, E. Roets, A. van Schepdael, J. Hoogmartens.
Isolation and structural characterization of polymyxin B components.
J Chromatogr A., 912 (2001), pp. 369-373
[6]
R.L. Nation, T. Velkov, J. Li.
Colistin and polymyxin B: Peas in a pod, or chalk and cheese?.
Clin Infect Dis., 59 (2014), pp. 88-94
[7]
R.V. Dudhani, R.L. Nation, J. Li.
Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage.
J Antimicrob Chemother., 65 (2010), pp. 1412-1415
[8]
M. Schindler, M.J. Osborn.
Interaction of divalent cations and polymyxin B with lipopolysaccharide.
Biochemistry., 18 (1979), pp. 4425-4430
[9]
Y.B. Guo, L.P. Chen, H.W. Cao, N. Wang, J. Zheng, G.X. Xiao.
Polymyxin B antagonizing biological activity of lipopolysaccharide.
Chin J Traumatol., 10 (2007), pp. 180-183
[10]
A.L. Kwa, V.H. Tam, M.E. Falagas.
Polymyxins: A review of the current status including recent developments.
Ann Acad Med Singapore., 37 (2008), pp. 870-883
[11]
B. Zhai, H. Zhou, L. Yang, J. Zhang, K. Jung, C.Z. Giam, et al.
Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.
J Antimicrob Chemother., 65 (2010), pp. 931-938
[12]
R. Ben-Ami, R.E. Lewis, J. Tarrand, K. Leventakos, D.P. Kontoyiannis.
Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.
Antimicrob Agents Chemother., 54 (2010), pp. 484-490
[13]
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty fifth informational supplement. CLSI document M100-25. Clinical and Laboratory Standards Institute. Wayne, PA; 2015.
[14]
European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. 2015 [consultado 15 Feb 2016]. Disponible en: http://www.eucast.org/
[15]
J. Li, R.L. Nation, J.D. Turnidge, R.W. Milne, K. Coulthard, C.R. Rayner, et al.
Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
Lancet Infect Dis., 6 (2006), pp. 589-601
[16]
Institute for Safe Medication Practices (ISMP). Warning! Dosing confusion with colistimethate for injection. 2011 [consultado 20 Jun 2014]. Disponible en: https://www.ismp.org/pressroom/PR20110629.pdf
[17]
D.E. Geller, W.H. Pitlick, P.A. Nardella, W.G. Tracewell, B.W. Ramsey.
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
Chest., 122 (2002), pp. 219-226
[18]
L.B. Palmer, G.C. Smaldone, S.R. Simon, T.G. O’Riordan, A. Cuccia.
Aerosolized antibiotics in mechanically ventilated patients: Delivery and response.
Crit Care Med., 26 (1998), pp. 31-39
[19]
American Thoracic Society/Infectious Disease Society of America.
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.
Am J Respir Crit Care Med., 171 (2005), pp. 388-416
[20]
A. Michalopoulos, D. Fotakis, S. Virtzili, C. Vletsas, S. Raftopoulou, Z. Mastora, et al.
Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: A prospective study.
Respir Med., 102 (2008), pp. 407-412
[21]
D. Berlana, J.M. Llop, E. Fort, M.B. Badia, R. Jodar.
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections.
Am J Health Syst Pharm., 62 (2005), pp. 39-47
[22]
N. Petrosillo, E. Ioannidou, M.E. Falagas.
Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies.
Clin Microbiol Infect., 14 (2008), pp. 816-827
[23]
W. Ni, X. Shao, X. Di, J. Cui, R. Wang, Y. Liu, et al.
In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: A systematic review and meta-analysis.
Int J Antimicrob Agents., 45 (2015), pp. 8-18
[24]
N.C. Gordon, K. Png, D.W. Wareham.
Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii.
Antimicrob Agents Chemother., 54 (2010), pp. 5316-5322
[25]
T.P. Lim, W. Lee, T.Y. Tan, S. Sasikala, J. Teo, L.Y. Hsu, et al.
Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B.
PLoS One., 6 (2011), pp. e28177
[26]
P. Gaibani, D. Lombardo, R.E. Lewis, M. Mercuri, S. Bonora, M.P. Landini, et al.
In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC- producing Klebsiella pneumoniae bloodstream isolates.
J Antimicrob Chemother., 69 (2014), pp. 1856-1865
[27]
N. Barth, V.B. Ribeiro, A.P. Zavascki.
In vitro activity of polymyxin b plus imipenem, meropenem, or Tigecycline against KPC-2-producing enterobacteriaceae with High MICs for these antimicrobials.
Antimicrob Agents Chemother., 59 (2015), pp. 3596-3597
[28]
A. Batirel, I.I. Balkan, O. Karabay, C. Agalar, S. Akalin, O. Alici, et al.
Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
Eur J Clin Microbiol Infec., 33 (2014), pp. 1311-1322
[29]
E. Durante-Mangoni, G. Signoriello, R. Andini, A. Mattei, M. de Cristoforo, P. Murino, et al.
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial.
Clin Infect Dis., 57 (2013), pp. 349-358
[30]
K.S. Kaye, J.M. Pogue, T.B. Tran, R.L. Nation, J. Li.
Agents of last resort: Polymyxin resistance.
Infect Dis Clin North Am., 30 (2016), pp. 391-414
[31]
M.K. Hayden, M.Y. Lin, K. Lolans, S. Weiner, D. Blom, N.M. Moore, et al.
Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long term acute care hospitals.
Clin Infect Dis., 60 (2015), pp. 1153-1161
[32]
Grupo de Microbiología, Subdirección Laboratorio Nacional de Referencia del Instituto Nacional de Salud [consultado 10 Ene 2016]. Disponible en: http://www.grebo.org/images/Alerta_Colombia_mcr1_salmonella_y_E_coli.pdf
[33]
Organización Panamericana de la Salud. Alerta epidemiológica. Enterobacterias con resistencia transferible a colistina. Implicaciones para la salud pública en las Américas.10 de junio de 2016 [consultado 10 Abr 2016]. Disponible en: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=35008⟨=es
